However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2026 have been unchanged by 0%, while EPS estimates have been unchanged by 0%. For the upcoming Q3 2026, revenue estimates have been adjusted revised downward by -36.18%. These revisions correlate with a -83.25% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in VTGN long-term fundamentals.

The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

RevenueEPS

Currency: USD

Revenue Estimate-:0

EPS Estimate-:0

—

Stock Price0

Revenue Estimates for FY2026

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2026

No Change

0.00%

In Past 3 Month

Revenue Estimates for Q3 2026

Revise Downward

-36.18%

In Past 3 Month

Stock Price

Go Down

-83.25%

In Past 3 Month

Earnings Forecast

Revenue

EPS

Currency: USD

Actual

Estimate

AI Analysis

Earnings Surprise Analysis

Revenue

EPS

AI Analysis

Earnings Reaction

The chart below shows how VTGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VTGN sees a -2.72% change in stock price 10 days leading up to the earnings, and a 0.14% change 10 days following the report. On the earnings day itself, the stock moves by -0.28%. This data can give you a slight idea of what to expect for the next quarter's release.

For example, in SEP/2025, the stock changed 0% on the day following the earnings release and then changed by 28.95% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

People Also Watch

Frequently Asked Questions

What were the key highlights of VTGN's latest earnings report for FY2026Q2?

VTGN reported its FY2026Q2 earnings on 2025-11-13, showcasing a revenue of 258.00K against an estimate of 145.80K, resulting in a 76.95% surprise. The EPS was -0.54, surpassing the expected -0.51 by -5.88%. The stock experienced a 0% price change on the earnings day and a 17.11% change over the next five days, reflecting market reactions to the results.

How did VTGN's stock price react after the FY2026Q2 earnings release?

Following VTGN's FY2026Q2 earnings announcement on 2025-11-13, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 17.11% change. Historically, VTGN's stock price tends to shift by an average of -2.72% in the 10 days leading up to earnings and 0.14% in the 10 days following, providing insight into potential market.

What are the revenue and EPS estimates for VTGN for 2026/Q4?

For 2026/Q4, analysts estimate VTGN's annual revenue to reach 191.80K, while the EPS is projected at -0.38. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -36.18% over the past three months, indicating analyst expectation in the company's performance.

How does VTGN's stock price correlate with earnings forecast revisions?

The correlation between VTGN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved revised downward by -36.18%. This trend suggests that price dips could present buying opportunities for investors.

What should investors expect from VTGN's next earnings report?

Based on historical trends, VTGN's stock price typically moves by -2.72% in the 10 days before its earnings and 0.14% in the 10 days after. For the upcoming 2026/Q4 earnings, analysts expect an EPS of -0.38 and revenue of 191.80K.

What is the sentiment in Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Summary?

The earnings call presents a mixed outlook. Positive aspects include ongoing trials and a solid cash position. However, regulatory challenges, placebo response issues, and operational efficiency concerns weigh negatively. The Q&A reveals uncertainty in data analysis and regulatory paths, with management's unclear responses potentially causing investor skepticism. Overall, the balance of positive and negative factors suggests a neutral stock price movement.

VTGN Earnings

VTGN Earnings

Quarterly Results

VTGN Earnings Forecast

Earnings Forecast

Earnings Surprise Analysis

People Also Watch

Frequently Asked Questions

What were the key highlights of VTGN's latest earnings report for FY2026Q2?

How did VTGN's stock price react after the FY2026Q2 earnings release?

What are the revenue and EPS estimates for VTGN for 2026/Q4?

How does VTGN's stock price correlate with earnings forecast revisions?

What should investors expect from VTGN's next earnings report?

What is the sentiment in Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Summary?